Jun 17, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
HealthLeaders-InterStudy And Fingertip Formulary To Release Report On Formulary Advan
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2422963" data-attributes="member: 124445"><p>HealthLeaders-InterStudy and Fingertip Formulary will release their latest report entitled Formulary Advantages in Therapies for Type 2 Diabetes: Crowding Among Anti-Diabetic Agents Necessitates Brand Differentiation: What Features Contribute to Preferred Reimbursement Status Among U.S. Health Plans? later this month. The report analyzes the reimbursement hurdles that brands such as Merck's Januvia, Eli Lilly/Amylin's Byetta and Novo Nordisk's Prandin will need to overcome in the face of Takeda's Actos (pioglitazone) patent expiry in 2012... <a href="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/JBxHeqF-_gQ" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/JBxHeqF-_gQ/3NLy" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2422963, member: 124445"] HealthLeaders-InterStudy and Fingertip Formulary will release their latest report entitled Formulary Advantages in Therapies for Type 2 Diabetes: Crowding Among Anti-Diabetic Agents Necessitates Brand Differentiation: What Features Contribute to Preferred Reimbursement Status Among U.S. Health Plans? later this month. The report analyzes the reimbursement hurdles that brands such as Merck's Januvia, Eli Lilly/Amylin's Byetta and Novo Nordisk's Prandin will need to overcome in the face of Takeda's Actos (pioglitazone) patent expiry in 2012... [URL="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/0/da"][IMG]http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/1/da"][IMG]http://feedads.g.doubleclick.net/~a/3S8YivFv-snIjrJCvqjYPcKfusg/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/JBxHeqF-_gQ[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/JBxHeqF-_gQ/3NLy]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top